Investor Relations

Tekmira Pharmaceuticals Corporation (NASDAQ:TKMRTSX:TKM) is a leading RNA interference (RNAi) therapeutics company. With more than 14 years of industry experience, Tekmira has established itself as a global leader in the RNAi field. Tekmira has a diverse pipeline of product candidates in development to treat serious human diseases such as cancer and viral infections like Hepatitis B and Ebola. The company is advancing the development of novel drugs in areas where there is a significant unmet medical need and commercial opportunity. Tekmira also licenses its leading LNP delivery technology to partners around the world.

View all »   RSSRecent Releases

Jul 21, 2014
Tekmira Provides Update on TKM-Ebola Phase I Clinical Hold

Jul 9, 2014
Tekmira Receives $1.5 Million Milestone Payment


View all »Events & Presentations

May 21, 2014
The 17th Annual Meeting of the American Society of Gene and Cell Therapy

May 14, 2014 at 1:30 PM PT
Tekmira Corporate Update and Q1 2014 Results